Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 352 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sham Injection Procedure Clear all
Recruiting Not applicable Interventional

Anti-Reflux Endoscopic TX Using APC (AREA) in GERD Patients: (The AREA Study)

NCT05570448
View directory record Official record
Conditions
Gastro Esophageal Reflux
Interventions
ARAT, Sham intervention (control)
Procedure
Lead sponsor
Midwest Veterans' Biomedical Research Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 30, 2026, 2:54 AM EDT
Terminated Phase 3 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

NCT03203447
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
suprachoroidal CLS-TA, suprachoroidal sham, Lucentis or Avastin
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 30, 2026, 2:54 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

NCT06510816
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Vonaprument, Sham Administration
Drug · Other
Lead sponsor
Annexon, Inc.
Industry
Eligibility
50 Years and older
Enrollment
659 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
71
States / cities
Scottsdale, Arizona • Beverly Hills, California • Fullerton, California + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 30, 2026, 2:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Intercostobrachial Nerve Block's Effect on Pain Control After Shoulder Replacement

NCT06042608
View directory record Official record
Conditions
Postoperative Pain, Acute, Shoulder Pain
Interventions
intercostobrachial nerve block
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 30, 2026, 2:54 AM EDT
Completed Phase 3 Interventional Results available

Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders

NCT04556552
View directory record Official record
Conditions
Substance-Related Disorders, Substance Use Disorders, Substance Abuse, Intravenous, Substance Withdrawal, Substance Abuse, Opioid-use Disorder, Opioid Use Disorder, Severe, Opioid Use
Interventions
Non invasive VN stimulation (nVNS), Oxygen (15-O) Water, Sham Stimulation
Device · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 30, 2026, 2:54 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment

NCT05730218
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment - Macula Off
Interventions
ONL1204 Ophthalmic Solution, Sham treatment
Drug
Lead sponsor
ONL Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
36
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 30, 2026, 2:54 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy

NCT07235085
View directory record Official record
Conditions
Non-Proliferative Diabetic Retinopathy
Interventions
Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24, Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24, Sham/mock procedure of intravitreal injection followed by a second sham/mock procedure at Week 24
Drug · Other
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
930 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Hagerstown, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 30, 2026, 2:54 AM EDT
Completed Not applicable Interventional Results available

A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal Incontinence

NCT00605826
View directory record Official record
Conditions
Fecal Incontinence
Interventions
NASHA/Dx (Solesta) Gel, Sham Injection
Device
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
8
States / cities
San Francisco, California • Tampa, Florida • Burlington, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 30, 2026, 2:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Infrapatellar Nerve Block for Post-operative Knee Arthroscopy Pain Control

NCT01279447
View directory record Official record
Conditions
Internal Derangement of Knee
Interventions
0.25% Bupivacaine, Normal Saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 30, 2026, 2:54 AM EDT
Completed Phase 2 Interventional Results available

A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration

NCT02181517
View directory record Official record
Conditions
Macular Degeneration
Interventions
abicipar pegol, ranibizumab, sham procedure
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 30, 2026, 2:54 AM EDT
Terminated Phase 3 Interventional Results available

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

NCT03810313
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 30, 2026, 2:54 AM EDT
Active, not recruiting Phase 2 Interventional

Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)

NCT06912633
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
human retinal progenitor cells, Mock injection
Biological · Other
Lead sponsor
jCyte, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 30, 2026, 2:54 AM EDT
Completed Phase 2 Interventional

A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

NCT03345082
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
OPT-302, ranibizumab, sham intravitreal injection
Biological · Other
Lead sponsor
Opthea Limited
Industry
Eligibility
50 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
55
States / cities
Phoenix, Arizona • Beverly Hills, California • Encino, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 30, 2026, 2:54 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy

NCT02193074
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
nusinersen, Sham procedure
Drug · Procedure
Lead sponsor
Biogen
Industry
Eligibility
Up to 210 Days
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 30, 2026, 2:54 AM EDT
Completed Not applicable Interventional Results available

Pulsed Radiofrequency vs. Steroid Injections for Occipital Neuralgia

NCT01670825
View directory record Official record
Conditions
Occipital Neuralgia
Interventions
Pulsed radiofrequency, Corticosteroid injection, Local anethestic injection
Procedure · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 30, 2026, 2:54 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration

NCT03038880
View directory record Official record
Conditions
Neovascularization, Choroidal, Macular Degeneration, Age-Related
Interventions
Faricimab, Ranibizumab, Sham Procedure
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 30, 2026, 2:54 AM EDT
Completed Phase 1Phase 2 Interventional

A Study to Evaluate Platelet Rich Plasma to Treat Vulvar Lichen Sclerosus

NCT04967170
View directory record Official record
Conditions
Vulvar Lichen Sclerosus
Interventions
Autologous Platelet-Rich Plasma (PRP), Sham Procedure
Biological · Other
Lead sponsor
Jennifer R. Arthurs
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 30, 2026, 2:54 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Paracervical Block for Pain Control With Osmotic Dilator Placement

NCT02354092
View directory record Official record
Conditions
Abortion Late, Pain
Interventions
Local anesthetic for tenaculum placement, Sham, Paracervical Block, Dilator Placement, Post-procedural assessment, Preprocedural pain control
Procedure · Behavioral · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 30, 2026, 2:54 AM EDT
Enrolling by invitation Phase 4 Interventional

Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy

NCT06191094
View directory record Official record
Conditions
Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
Interventions
Faricimab Injection, sham treatment
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 30, 2026, 2:54 AM EDT
Terminated Phase 2 Interventional Results available

Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration

NCT02222207
View directory record Official record
Conditions
Macular Degeneration
Interventions
Regorafenib, ophthalmic oily suspension (BAY73-4506), Sham IVT, Ranibizumab, Placebo
Drug · Procedure
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
37
States / cities
Tucson, Arizona • Arcadia, California • Beverly Hills, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Oct 30, 2026, 2:54 AM EDT
Active, not recruiting Phase 3 Interventional

Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine

NCT05516992
View directory record Official record
Conditions
Lumbar Degenerative Disc Disease
Interventions
SB-01 For Injection, Sham Needle
Drug
Lead sponsor
Spine BioPharma, Inc
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Napa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 30, 2026, 2:54 AM EDT
Terminated Phase 1 Interventional Results available

Stellate Ganglion Blockade in Corona Virus 2019 (COVID-19) Positive Patients

NCT04445337
View directory record Official record
Conditions
COVID 19, ARDS
Interventions
Stellate Ganglion Block
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 30, 2026, 2:54 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema

NCT03622593
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Aflibercept, Faricimab, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
50
States / cities
Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 30, 2026, 2:54 AM EDT
Completed Not applicable Interventional Results available

Randomized Evaluation of the Efficacy of Synvisc-One® for the Treatment of Patellofemoral Chondromalacia

NCT01771952
View directory record Official record
Conditions
Chondromalacia Patella, Patellofemoral Pain Syndrome
Interventions
Synvisc-One™, Sham Treatment
Device · Other
Lead sponsor
University of Virginia
Other
Eligibility
15 Years to 45 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 30, 2026, 2:54 AM EDT